

New Journal of Chemistry


Supporting Information

Gold/iron oxide coreshell nanostructures for oxidation of indoles and synthesis of uracil-derived spirooxindoles

Shivaneer B. Gohain,^a Purna K. Boruah,^b Manash R. Das^b and Ashim J. Thakur^{*a}

^aDept. Of Chemical Sciences, Tezpur University, Napaam 784028, Assam, INDIA; ^bAdvanced Materials Group, Materials Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Jorhat 785006, Assam, India

Graphical abstract:



Synthesis of isatins and uracil based spirooxindoles catalysed by Au/Fe₃O₄ core shell nanoparticles under mild condition and low reaction times.

List of contents

(1)	General Experimental Methods.....	S3
(2)	Preparation of catalysts.....	S3
(3)	Characterization of the catalysts.....	S4
(4)	General Synthetic Procedures.....	S4
(5)	Recycling potentials of nanocatalysts.....	S5
(6)	List of figures.....	S5
(7)	List of tables.....	S11
(8)	Physical and Spectroscopic data of compounds.....	S16
(9)	¹ H NMR and ¹³ C NMR spectra of compounds.....	S23
(10)	List of selected previous works.....	S40
(11)	NOE NMR of compound	S41
(12)	Calculation of Fe content in the catalyst Fe ₃ O ₄ /AuNPs-GO.....	S44
(13)	References.....	S45

(1) General Experimental Methods

All chemicals were purchased from Sigma-Aldrich, Merck, Alfa Aesar and Loba chemical, and used without any further purification. $\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$ (99% purity) and $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (99% purity) were procured from Sigma-Aldrich. Deionized water was used for the preparation of catalyst. Graphite (98% purity) was purchased from Loba Chemie. The solvents used in different reactions were purchased from E-Merck. Melting points were determined in a Büchi 504 apparatus. ^1H and ^{13}C NMR spectra were recorded in a 400 MHz NMR spectrophotometer (JEOL, JNM ECS) using tetramethylsilane (TMS) as the internal standard and coupling constants are expressed in Hertz. Visualization of organic products was accomplished with UV lamp or I_2 stain. The reactions were monitored by thin-layer chromatography using aluminium sheets with silica gel 60 F₂₅₄ (Merck).

(2) Preparation of catalysts

Preparation of GO.

GO was prepared by oxidizing graphite according to the modified Hummer's method.^[1,2]

Preparation of $\text{Fe}_3\text{O}_4/\text{AuNPs}$

Fe_3O_4 NPs were prepared by the reduction of Fe^{2+} with NaBH_4 . A total of 0.2 g (1.3 mmol) of FeSO_4 was added to 0.1 g (2.8 mmol) of NaBH_4 and the mixture was stirred at room temperature for 1 h. A dark powder was obtained, to which 100 mL of distilled water was added. To create Au shell on the Fe core, 0.05 g (0.16 mmol) of HAuCl_4 was added to the solution of FeSO_4 and NaBH_4 . The resulting black solution was heated to 100 °C. A total of 0.4 g (1.5 mmol) of the trisodium citrate solution in 10 mL of water was immediately added to the solution, and it was left stirring (~1400 rpm) at room temperature overnight. A black colloidal solution was obtained. The sample was dried in a vacuum for elemental analysis.

Preparation of $\text{Fe}_3\text{O}_4/\text{Au NPs-rGO}$.

Fe-Au NPs were synthesized according to the above-mentioned method. The mixture of 80 mL aqueous solution of Fe NPs and 1g of GO was stirred at room temperature overnight, and the product was dried at 40 °C overnight.

(3) Characterization of the catalysts

The UV-visible spectra of Au nano catalysts were recorded on UV-Visible spectrophotometer (Hitachi, U-2001, Shimadzu, UV-2550 Model Cary 100 Bio). Field mission transmission electron microscopy (FETEM) images and energy dispersive Xray (EDX) analyses of nanocatalysts were carried out on JEOL (Model 2100F) and Tecnai G2 20 S-Twin (200kV) TEM. X-ray diffraction (XRD) measurement was performed on Bruker AXS, model D8 Focus. Scanning electron microscopy (SEM) and electron-dispersive X-ray spectroscopy (EDS or EDX) mapping were done in JEOL, Japan, model JSM 6390LV. The high-resolution X-ray photoelectron spectroscopy (XPS) measurements using a Thermo-Scientific ESCALAB Xi+ spectrometer with a monochromatic Al K α X-ray source (1486.6 eV).

(4) General Synthetic Procedures

(A) General Procedure for synthesis of 2,3-indolinones (isatins)

For a typical reaction (Scheme 1), nanocatalyst and solvent (3 ml) were added into the reaction vessel and then followed by indole (0.5 mmol). The reaction vessel was sealed and stirred at room temperature for 6 h. After its completion, ethyl acetate (3x10 mL) was added to it and then centrifuged at 3,500 rpm to recover the nano catalyst. Having done this, the reaction mixture was washed with water and brine, dried over Na₂SO₄, concentrated in a rotary evaporator and finally the crude product was purified by column chromatography (30% ethyl acetate: hexane as an eluent).

(B) General Procedure for synthesis of spiroxindoles

For a typical reaction (Scheme 2), nanocatalyst and solvent (3 ml) were added into the reaction vessel and then followed by indole (0.5 mmol), malononitrile (0.5 mmol) and

6-amino-1-methyluracil (0.5 mmol). The reaction vessel was sealed and stirred at room temperature for 5 min. After its completion, methanol (1x10 mL) was added to it and then centrifuged at 3,500 rpm to recover the nano catalyst. Having done this, the reaction mixture filtered through Whatmann filter paper No. 1 and the products were recrystallised.

(5) Recycling potentials of nanocatalysts

After carrying out the experiment, ethyl acetate was added, and the reaction mixture was centrifuged to pellet out the Fe₃O₄/Au NPs-rGO nanocomposite. The particles were then extracted by simple centrifugation (3,000 rpm) and washed with hot ethanol (3x10 mL) to remove all the organic impurities. Finally, it was decanted and dried in vacuum. The recovered nanocatalyst was used directly in the next cycle. The Fe₃O₄/Au NPs-rGO nanocomposite was found to be equally effective up to 3rd and 4th cycle (Fig. S12, ESI) for isatin and spirooxindole synthesis respectively, and after that the product yield slightly decreases.

(6) List of figures




Figure S1. Examples of isatin based moieties in the potential drugs designed inhibitors for SARS-CoV-2




Figure S2. Examples of spirooxindole derived compounds with anti-cancer properties



Figure S3. (a) Image of Fe₃O₄/Au NPs and Image of Fe₃O₄/Au NPs-rGO




Figure S4. Schematic representation of formation of gold (yellow) coated iron oxide (red) NPs and gold coated iron oxide NPs supported on *in-situ* synthesized reduced graphene oxide (black)




Figure S5(i). FETEM images of Fe₃O₄/Au NPs (inset in (b) shows SAED pattern; inset in (d) shows lattice fringe pattern of Au and Fe₃O₄ NPs




Figure S5(ii). FETEM images of Fe₃O₄/Au NPs-rGO (inset in (b) shows SAED pattern; inset in (d) shows lattice fringe pattern of Au and Fe₃O₄ NPs)




Figure S5(iii). XPS high resolution spectra of (a) Au 4*f* (b) C 1*s* (c) Fe 2*p* and (d) O 1*s* of Fe₃O₄/Au NPs




Figure S5(iv). XPS high-resolution spectra of (a) Au 4*f* (b) C 1*s* (c) Fe 2*p* and (d) O 1*s* of Fe₃O₄/Au NPs-rGO.




Figure S6. SEM images of the (a) Fe₃O₄/Au NPs and (b) Fe₃O₄/Au NPs-rGO




Figure S7. XRD pattern of Fe₃O₄/Au NPs (red), Fe₃O₄/Au NPs-rGO (blue)




Figure S8. FTIR spectra of Fe₃O₄/Au NPs (black) and Fe₃O₄/Au NPs-rGO (red)




Figure S9. EDX spectra of (a) Fe₃O₄/Au NPs and (b) Fe₃O₄/Au NPs-rGO




Figure S10. Raman spectra of (a) GO and (b) Fe₃O₄/Au NPs-rGO




Figure S11. TGA curve of Fe₃O₄/Au NPs-rGO




Figure S12. Catalyst recyclability chart of Fe₃O₄/Au NPs-rGO for a) isatin and b) spirooxindole synthesis

(7) List of tables


Table S1. Observed infrared band positions for Fe₃O₄/Au NPs and Fe₃O₄/Au NPs-rGO

Peak assignments	Fe ₃ O ₄ /Au NPs	Peak assignments	Fe ₃ O ₄ /Au NPs-rGO
Hydroxyl stretch	3443	Hydroxyl stretch	3443
CH of citrate	2922	CH ₂ stretching of alcohol groups of GO	2929
CH of citrate	2848	CH ₂ stretching of alcohol groups of GO	2848
symmetric C=O stretching from the COOH group of citrate	1630	C=C stretches from unoxidized graphitic domain	1630
asymmetric stretching of C-O from COOH group of citrate	1349		
	1116	C-O stretching vibrations of C-O-C stretching of GO to C-O stretching vibrations of C-O stretching of G	1130
		Fe-O stretching vibrational mode of Fe ₃ O ₄	1056
			596

Table S2. Atomic percentage of different elements in the nanomaterials

(Nano Au)	Fe	O	Au	C
Fe ₃ O ₄ /Au NPs	6.53	92.05	1.43	-
Fe ₃ O ₄ /Au NPs-rGO	0.81	35.59	0.43	63.17


Table S3. Optimisation of reaction conditions for oxidation of indole to isatin catalysed by Fe₃O₄/Au NPs-rGO^[a]



Sl. No.	Catalyst (mg)	TBHP (μL)	Solvent	Temp. (° C)	% Yield ^[b]
1	0.1	-	Toluene	25	[c]
2	0.1	100	Toluene	25	30
3	0.1	100	MeOH	25	40
4	0.1	100	Isopropanol	25	32
5	0.1	100	Water	25	31
6	0.1	100	EtOH	25	28
7	0.1	100	DCM	25	Traces
8	0.1	100	MeOH	80	56
9	0.1	100	ACN	25	75
10	0.1	100	ACN	50	74
11	0.1	100	ACN	80	78
12	0.1	100	ACN	100	72
13	0.1	100	ACN	25	65 ^[d]
14	0.1	100	ACN	25	45 ^[e]
15	0.1	100	ACN	25	77 ^[f]
16	0.1	100	ACN	25	78 ^[g]
17	0.1	100	ACN	25	77 ^[h]
18	0.1	100	ACN	25	69 ^[i]
19	0.1	100	ACN	25	64 ^[j]
20	0.1	1	ACN	25	24
21	0.1	5	ACN	25	30
22	0.1	10	ACN	25	33
23	0.001	100	ACN	25	28
24	0.01	100	ACN	25	45


[a]Reaction conditions: **2a** (0.5 mmol), catalyst Fe₃O₄/Au NPs-rGO(0.1 mg) in solvent (3 mL) for 6 h. [b]Isolated yield. [c]No conversion was detected. Reaction for 3h[d], 1h[e], 12[f] and 24h[g]. Reaction with solvent amount of 2mL[h], 1 mL[i] and 10 mL[j].

Table S4. Scope of reaction for oxidation of indole to isatin catalysed by Fe₃O₄/Au NPs-rGO



[a]Reaction conditions: **3a** (0.5 mmol), catalyst Fe₃O₄/Au NPs-rGO (0.1 mg) in MeCN (3 mL) for 6 h at RT.



Table S5. Optimisation of reaction conditions for synthesis of spirooxindole catalysed by Fe₃O₄/Au NPs-rGO^[a]



Sl. No.	Catalyst (mg)	Ratio of amount of substrate (5a:5b:5c)	Solvent	% Yield ^[b]
1	0.1	1:1:1	-	[c]
2	0.1	1:1:1	EtOH	70
3	0.1	1:1:1	MeOH	72
4	0.1	1:1:1	Isopropanol	65
5	0.1	1:1:1	Water	60
6	0.1	1:1:1	EtOH;Water (1:1)	80
7	0.1	1:1:1	EtOH;Water (2:1)	75
8	0.1	1:1:1	EtOH;Water (1:2)	70
9	0.1	2:1:1	EtOH;Water (1:1)	76
10	0.1	1:2:1	EtOH;Water (1:1)	79
11	0.1	1:1:2	EtOH;Water (1:1)	77
12	0.001	1:1:1	EtOH;Water (1:1)	40
13	0.01	1:1:1	EtOH;Water (1:1)	37
14	0.1	1:1:1	EtOH;Water (1:1)	79 ^[d]
15	0.1	1:1:1	EtOH;Water (1:1)	56 ^[e]
16	0.1	1:1:1	EtOH;Water (1:1)	80 ^[f]
17	0.1	1:1:1	EtOH;Water (1:1)	68 ^[g]
18	0.1	1:1:1	EtOH;Water (1:1)	55 ^[h]

[a]Reaction conditions: **6a** (0.5 mmol), **6b** (0.5 mmol), **6c** (0.5 mmol), catalyst Fe₃O₄/Au NPs-rGO (0.1 mg) in solvent (3 mL) for 5 min. [b]Isolated yield. [c]No conversion was detected. Reaction at 40 °C^[d] and 80 °C^[e] Reaction for 10 min^[f], 3 min^[g] and 2 min^[h].


Table S6. Scope of reaction for the synthesis of spirooxindole catalysed by Fe₃O₄/Au NPs-GO^[a]



[a]Reaction conditions: **7a** (0.5 mmol), **7b** (0.5 mmol), **7c** (0.5 mmol), catalyst Fe₃O₄/Au NPs-rGO (0.1 mg) in solvent (3 mL) for 5 min.


(8) Physical and Spectroscopic Data of Compounds

Indoline-2,3-dione (Table 3, entry 3a)




Orange solid; 75%; m.p. 198 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.66 (s, 1H), 8.44 (dd, *J* = 8.8, 2.6 Hz, 1H), 8.21 (d, *J* = 2.8 Hz, 1H), 7.09 (d, *J* = 8.8 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 184.4, 159.4, 150.7, 138.4, 124.7, 122.8, 117.9, 112.2 ppm; IR (KBr) $\tilde{\nu}$ = 3451, 1737, 1620, 1466, 1327 cm⁻¹.

5-Methoxyindoline-2,3-dione (Table 3, entry 3b)




Red solid; 88%; m.p. 199 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= δ 10.84 (s, 1H), 7.18 (dd, *J* = 8.6, 2.9 Hz, 1H), 7.07 (d, *J* = 3.3 Hz, 1H), 6.84 (d, *J* = 8.6 Hz, 1H), 3.74 (s, 3H) ppm; ¹³C NMR (100MHz, DMSO-*d*₆): δ= 184.7, 159.6, 155.3, 144.7, 124.9, 118.1, 113.2, 108.8, 55.8 ppm; IR (KBr) $\tilde{\nu}$ = 3441, 3182, 1644, 1749, 1308 cm⁻¹.

5-Chloroindoline-2,3-dione (Table 3, entry 3c)




Orange solid; 84%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.13 (s, 1H), 7.99-7.43 (m, 2H), 6.92 (d, *J* = 8.6 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 183.4, 159.2, 149.2, 137.3, 126.8, 124.2, 119.2, 113.9 ppm; IR (KBr) $\tilde{\nu}$ = 3462, 3185, 1755, 1709, 1611 cm⁻¹.

5-Nitroindoline-2,3-dione (Table 3, entry 3d)




Yellow solid; 79%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.66 (s, 1H), 8.44 (dd, *J* = 8.8, 2.5 Hz, 1H), 8.21 (d, *J* = 2.7 Hz, 1H), 7.08 (d, *J* = 9.2 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 182.4, 159.9, 155.2, 142.6, 133.1, 119.6, 118.1, 112.5 ppm; IR (KBr) $\tilde{\nu}$ = 3335, 1764, 1615, 1536, 1326 cm⁻¹.

1-Methylindoline-2,3-dione (Table 3, entry 3e)




Brown solid; 74%; m.p. 131 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.03 (s, 1H), 7.53 (m, 1H), 7.06 (td, *J* = 7.6, 1.0 Hz, 1H), 6.94-6.87 (m, 1H), 3.33 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 183.53, 158.19, 151.38, 138.17, 124.28, 123.19, 117.40, 110.65 ppm; IR (KBr) $\tilde{\nu}$ = 3448, 2926, 1733, 1613, 1465 cm⁻¹.

5-Bromoindoline-2,3-dione (Table 3, entry 3f)




Brown solid; 80%; m.p. >200 °C; ¹H NMR (400 MHz, Methanol-*d*₄): δ= 7.59 (dd, *J* = 2.0, 0.6 Hz, 1H), 7.25 (dd, *J* = 8.6, 0.6 Hz, 1H), 7.15 (dd, *J* = 8.8, 2.2 Hz, 1H), 7.01 (s, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 183.9, 159.7, 149.7, 137.8, 127.3, 124.6, 119.7, 114.3 ppm; IR (KBr) $\tilde{\nu}$ = 3444, 2923, 1762, 1248, 1049 cm⁻¹.

6-Bromoindoline-2,3-dione (Table 3, entry 3g)




Brown solid; 78%; m.p. >200 °C; ¹H NMR (400 MHz, Methanol-*d*₄): δ= 7.50 (dd, *J* = 1.9, 0.6 Hz, 1H), 7.39 (dd, *J* = 8.5, 0.6 Hz, 1H), 7.06 (dd, *J* = 8.5, 1.8 Hz, 1H), 6.99 (t, *J* = 1.1 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 183.8, 159.6, 149.7, 137.8, 127.3, 124.6, 119.6, 114.3 ppm; IR (KBr) $\tilde{\nu}$ = 3465, 2992, 1745, 1378, 1242 cm⁻¹.

7'-Amino-1'-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6a)




Brick red solid; 80%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.21 (s, 1H), 10.31 (s, 1H), 7.89 (d, *J* = 8.5 Hz, 1H), 7.57 (t, *J* = 8.4 Hz, 1H), 7.14 (t, *J* = 8.3 Hz, 1H), 6.94 (d, *J* = 8.3 Hz, 1H), 6.76 (s, 1H), 4.54 (d, *J* = 2.4 Hz, 1H), 3.17 (s, 3H), 2.08 (s, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 163.8, 162.3, 156.4, 151.3, 150.7, 146.5, 137.8, 125.9, 122.9, 118.7, 113.1, 111.7, 111.6, 80.6, 75.2 ppm; IR (KBr) $\tilde{\nu}$ = 3429, 3261, 1716, 1616, cm⁻¹.

7'-Amino-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6b)




Red solid; 72%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.21 (s, 1H), 7.88 (d, *J* = 8.5 Hz, 1H), 7.57 (td, *J* = 7.9, 1.3 Hz, 1H), 7.14 (td, *J* = 7.8, 1.1 Hz, 1H), 6.94 (d, *J* = 8.0 Hz, 1H), 3.23 (s, 1H), 3.06 (s, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 163.9, 150.8, 146.5, 137.9, 137.9, 125.9, 123.0, 122.9, 118.7, 113.1, 111.7, 111.7, 111.6, 80.7 ppm; IR (KBr) $\tilde{\nu}$ = 3439, 3261, 1715, 1627, 1586 cm⁻¹.

7'-Amino-5-methoxy-1'-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6c)




Black solid; 93%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.01 (s, 1H), 7.38 (d, *J* = 2.9 Hz, 1H), 7.21 (dd, *J* = 8.7, 2.7 Hz, 1H), 6.87 (d, *J* = 8.7 Hz, 1H), 6.76 (s, 1H), 4.54 (d, *J* = 2.4 Hz, 1H), 3.75 (s, 5H), 3.16 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 163.8, 162.4, 156.4, 151.3, 150.9, 140.6, 124.2, 119.1, 113.09, 112.6, 111.5, 110.2, 80.91, 75.2, 55.8 ppm; IR (KBr) $\tilde{\nu}$ = 3385, 3177, 1713, 1588, 1491 cm⁻¹.

7'-Amino-5-methoxy-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6d)




Royal Blue solid; 78%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.00 (s, 1H), 8.31 (s, 1H), 7.38 (d, *J* = 2.8 Hz, 1H), 7.21 (m, 1H), 6.87 (d, *J* = 9.0 Hz, 1H), 3.75 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 163.8, 154.9, 150.8, 140.6, 124.2, 124.1, 119.1, 113.0, 112.6, 112.5, 111.5, 110.3, 110.2, 80.9, 55.8, 55.7 ppm; IR (KBr) $\tilde{\nu}$ = 3388, 2224, 1715, 1592, 1484 cm⁻¹.

7'-Amino-5-chloro-1'-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6e)




Brown solid; 85%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 7.91 (d, *J* = 8.7 Hz, 1H), 7.66 (t, *J* = 8.6 Hz, 1H), 7.27-7.08 (m, 2H), 3.15 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 163.6, 162.4, 156.4, 151.3, 149.7, 145.2, 137.0, 126.5, 124.8, 120.1, 113.4, 112.8, 111.2, 82.4, 75.2, 28.3 ppm; IR (KBr) $\tilde{\nu}$ = 3588, 3515, 2983, 1736, 1598 cm⁻¹.

7'-Amino-5-chloro-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6f)




Dark brown solid; 80%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.37 (s, 1H), 7.77 (s, 1H), 7.64 (d, *J* = 10.7 Hz, 1H), 6.97 (d, *J* = 8.9 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 163.6, 149.7, 145.2, 137.0, 136.9, 126.5, 124.8, 124.7, 120.0, 113.4, 112.8, 111.2, 82.3 ppm; IR (KBr) $\tilde{\nu}$ = 3581, 3513, 2990, 1733, 1596 cm⁻¹.

7'-Amino-1,1'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6g)




Black solid; 90%; m.p.>200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.36 (s, 1H), 7.77 (d, *J* = 2.3 Hz, 1H), 7.68-7.59 (m, 1H), 6.97 (dd, *J* = 8.6, 1.6 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 163.5, 149.7, 145.2, 136.9, 136.9, 126.5, 124.8, 124.8, 120.0, 113.4, 113.3, 112.8, 111.2, 82.3 ppm; IR (KBr) $\tilde{\nu}$ = 3371, 3180, 2235, 1722, 1598 cm⁻¹.

7'-Amino-1,1',3'-trimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6h)




Dark brown solid; 81%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 7.91 (d, *J* = 5.7 Hz, 2H), 7.67 (dd, *J* = 9.1, 6.1 Hz, 2H), 7.16 (tt, *J* = 15.2, 7.6 Hz, 5H), 3.15 (s, 6H), 3.13 (s, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 183.5, 162.5, 158.2, 151.4, 149.8, 147.2, 137.7, 137.7, 125.5, 118.1, 117.4, 112.9, 111.5, 110.6, 110.5, 81.2, 26.3, 26.3 ppm; IR (KBr) $\tilde{\nu}$ = 3427, 2231, 1718, 1594, 1469 cm⁻¹.

7'-Amino-1'-methyl-5-nitro-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6i)



Red solid; 95%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.93 (s, 1H), 10.31 (s, 1H), 8.66 (s, 1H), 8.45 (d, *J* = 10.9 Hz, 1H), 7.15 (d, *J* = 9.0 Hz, 1H), 6.77 (s, 1H), 3.16 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-D₆): δ= 179.9, 160.4, 150.9, 149.9, 148.3, 146.5, 142.4, 137.4, 125.6, 119.2, 118.3, 109.19, 85.6, 56.9, 49.2, 29.1 ppm; IR (KBr) $\tilde{\nu}$ = 3580, 3522, 2829, 1729, 1338 cm⁻¹.



7'-Amino-1',3'-dimethyl-5-nitro-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6j)





Red solid; 88%; m.p. >200 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ= 11.94 (s, 1H), 8.65 (s, 1H), 8.45 (d, *J* = 10.7 Hz, 1H), 7.14 (d, *J* = 10.2 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-*d*₆): δ= 164.1, 151.2, 149.3, 142.4, 132.7, 120.7, 118.8, 112.6, 111.9, 110.9, 83.5 ppm; IR (KBr) $\tilde{\nu}$ = 3583, 3512, 2839, 1728, 1341 cm⁻¹.

(9) ^1H NMR and ^{13}C NMR spectra of compounds



Indoline-2,3-dione (Table 3, entry 3a)



5-Methoxyindoline-2,3-dione (Table 3, entry 3b)





5-Chloroindoline-2,3-dione (Table 3, entry 3c)




5-Nitroindoline-2,3-dione (Table 3, entry 3d)




5-Bromoindoline-2,3-dione (Table 3, entry 3f)





6-Bromoindoline-2,3-dione (Table 3, entry 3g)





7.50
7.50
7.50
7.41
7.40
7.38
7.08
7.07
7.05
6.99
6.98





183.86
159.64
149.73
137.80
127.32
124.68
119.66
114.34





7'-Amino-1'-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6a)





7'-Amino-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6b)





7'-Amino-5-methoxy-1'-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6c)





7'-Amino-5-methoxy-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6d)





7'-Amino-5-chloro-1'-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6e)





7'-Amino-5-chloro-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6f)





7'-Amino-1,1'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6g)





7'-Amino-1,1',3'-trimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6h)



7'-Amino-1'-methyl-5-nitro-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6i)



7'-Amino-1',3'-dimethyl-5-nitro-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'H-spiro[indoline-3,5'-pyrido[2,3-d]pyrimidine]-6'-carbonitrile (Table 5, entry 6j)



(10) Table S7. List of selected previous works

Sl. No.	Starting Material	Conditions	Product	Time (h)	Yield (%)	Reference
1	<i>N</i> -protected indoles	indole (0.5 mmol), Cu(OAc) ₂ (0.025 mmol), TBHP (70% wt in H ₂ O, 1.0 mL), CH ₃ CN (3.0 mL), 50 °C	Isatin	12 h	0-90	3
2	<i>N</i> -protected indoles	indole (0.5 mmol), Pd(OAc) ₂ (10 mol %), TBHP (70% wt in H ₂ O, 1.0 mL), CH ₃ CN (3.0 mL), 80 °C	Isatin	1 h	0-75	4
3	Indoles	indole (1 mmol), NIS (1.3 equiv.), IBX (3 equiv.), DMSO (2.0 mL), 25 °C	Isatin	3 h	73-89	5
4	Isatin, 5-amino-1,4-dimethyluracil, malonitrile	isatin (1 mmol), 5-amino-1,4-dimethyluracil (1 mmol), malonitrile (1 mmol), Fe ₃ O ₄ @SiO ₂ -TCTTheophylline (0.015, 0.85 mol%), H ₂ O (3 mL), reflux	Uracil-based spiroxindole	6-12 h	90-95	6

(11) NOE NMR spectrum of compound




Figure S13. COSY NMR (in DMSO-*d*₆) of 7'-Amino-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, **entry 6b**)




Figure S14. A representative ^1H - ^1H COSY spectrum (in $\text{DMSO-}d_6$) of 7'-Amino-1',3'-dimethyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, **entry 6b**)




Figure S15. COSY NMR (in $\text{DMSO-}d_6$) of 7'-Amino-5-methoxy-1'-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, **entry 6c**)




Figure 16. A representative ^1H - ^1H COSY spectrum (in $\text{DMSO-}d_6$) of 7'-Amino-5-methoxy-1-methyl-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, **entry 6c**)




Figure 17. COSY NMR (in $\text{DMSO-}d_6$) of 7'-Amino-1',3'-dimethyl-5-nitro-2,2',4'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, **entry 6j**)




Figure 18. A representative ^1H - ^1H COSY spectrum (in $\text{DMSO-}d_6$) of 7'-Amino-1',3'-dimethyl-5-nitro-2,2',4',8'-trioxo-2',3',4',8'-tetrahydro-1'*H*-spiro[indoline-3,5'-pyrido[2,3-*d*]pyrimidine]-6'-carbonitrile (Table 5, entry 6j)

(12) Calculation of Fe content in the catalyst $\text{Fe}_3\text{O}_4/\text{Au}$ NPs-GO

0.2g $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ solution in 110 mL was taken for preparation of $\text{Fe}_3\text{O}_4/\text{Au}$ NPs.

$(0.2/110 \times 1000)$ g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ in 1000 mL H_2O .

% of Fe in $\text{FeSO}_4 \cdot 7\text{H}_2\text{O} = 55.85/278.01 \times 100 = 20.09\%$

20.09% of $(0.2/110 \times 1000)$ g of $\text{FeSO}_4 = (0.2/110 \times 1000) \times (20.09/100) = 0.365$ g

So, 0.365 g of Fe in 1000 mL H_2O .

Or $(0.365 \times 80)/1000 = 0.0292$ g in 80 mL H_2O .

According to AAS of the decanted solution (supernatant) of $\text{Fe}_3\text{O}_4/\text{Au}$ NPs-GO, concentration of Fe is 178.75 mg/L i.e. 0.17875 g/L.

Or (0.17875×80) mL = 14.3 mg or 0.0143 g in 80 mL H_2O .

So, concentration of Fe in the catalyst $\text{Fe}_3\text{O}_4/\text{Au}$ NPs-GO = (Concentration of Fe taken for the reaction) – (Concentration of Fe in 80 mL of supernatant solution)
 = $(0.0292 - 0.0143)$ g

= 0.0149 g in 250 mg catalyst

Thus, 0.1 mg of catalyst will contain = $(0.0149 \times 0.1)/250$ g

= 0.000006 g Fe

= 0.006 mg Fe

For calculating the mol%, the formula is shown below,

Reactant (g)/ Molar mass of the reactant (g/mol) \times mol% \times Catalyst molar mass (g/mol)

= Weight of catalyst (g)

for which the molar mass of the catalyst is to be known. As the molar mass of the support (graphene oxide) is not able to be defined with respect to atomic mass, so the weight of the catalyst is taken as reference for the reaction conditions in application of the catalyst in synthesis of indolinones and spirooxindoles.

(13) References

- [1] W. S. Hummers, R. E. Offeman, *J. Am. Chem. Soc.*, 1958, **80**, 1339
- [2] S. Thakur, N. Karak, *RSC Adv.*, 2013, **3**, 9476-9482.
- [3] J. Luo, Y. Zhao, X. Xu, J. Zheng, H. Liang, *Tetrahedron Lett.*, 2017, **58**, 4591-4594.
- [4] J. Luo, S. Gao, Y. Ma, G. Ge, *Synlett*, 2018, **29**, 969-973.
- [5] A. Chandra, N. R. Yadav, J. N. Moorthy, *Tetrahedron*, 2019, **75**, 2169-2174.
- [6] M. Esmaeilpour, A. R. Sardarian, H. Firouzabadi, *ChemistrySelect*, 2018, **3**, 9236-9248.